Immunogenicity & Immunotoxicity
Immunotherapeutics & Immunomonitoring
Cytokines & Inflammation
Over the years, GTCbio’s 16th Cytokines & Inflammation Conference has become an established meeting point for academic scientists, industry clinical developers, and government researchers to discuss complementary approaches in the field of cytokine biology. We are excited to announce the 16th annual edition of this meeting, which will take place in San Diego, CA.
Joint Plenary Sessions:
- Opening Keynote Session – Historical Perspective & Current State of the Industry
- Round Table Discussions
- Ready, Set, Grow! – New Company Pitch Competition
- Award Ceremony & Closing Keynote Session – Predictions for future
Cytokines & Inflammation:
- Metabolic Regulation of Immunity & Inflammation
- Influence of Microbiome on Immune Responses
- Targeting Cytokines for Therapeutic Interventions
- Innate Immunity in Respiratory Diseases
Please join us for not only presentations on the latest research, but networking sessions where you will meet and collaborate with fellow researchers on the future of cytokines research! We hope to see you in San Diego!
The 2018 Advisory Committee
What Past Delegates Said About the Cytokines & Inflammation Conference:
“The GTCbio Meeting provided a unique opportunity for a select group of scientists from biotechnology, pharmaceutical companies and academia to communicate and interact in a very pleasant setting. The program covered not only fundamental advances, but also translational and diagnostic applications of the latest findings.”
– Joost J. Oppenheim, Chief of the Laboratory of Molecular Immunoregulation, NCI, NIH
“The Cytokines Conference provided great opportunities for networking among folks from academia, industry, and regulatory agencies. The presentations were a great mix of high-powered molecular biology and clinical applications of anti-cytokine therapies.”
– Phillip K. Weck, Ph.D., Vice President & CDTL, Immunology R&D, Janssen
“Energizing and inspiring, intimate conference. The new ideas and connections are worth the investment.”
– Francisco Leon, Vice President, Janssen R&D
“Great value with an opportunity to meet colleagues in a convivial atmosphere, erudite state of the art presentations, and compact format designed to capture the current major thrusts in science.”
– Michael Lotze, Professor of Surgery and Bioengineering, University of Pittsburgh
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
ACEA Biosciences, Inc. is a pioneer in the development and commercialization of highperformance microelectronic systems for cell-based assays. ACEA’s xCELLigence® systems are widely used in academic labs, government institutions, biotech and pharma companies around the world to study cell adhesion, cell migration/invasion, GPCR/RTK signaling, cell proliferation and compound/cell/viral-mediated cytotoxicity.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
SQI Diagnostics is a life sciences company that provides clinical grade multiplexed assays and its automated instrumentation to the pharmaceutical research market. SQI develops custom ADA, epitope mapping, multiplexed PK assays, biomarker, and many other assays all in one well making it the leader in the multiplexing of therapeutic proteins, isotypes and subclasses in a single well.
Our goal is simply to help researchers gain a better understanding of proteins and their role in disease. We develop and commercialize proprietary systems and consumables for protein analysis that ultimately help reveal new insights into the true nature of proteins. Our goal is to make protein analysis simpler, more quantitative and affordable. Our comprehensive portfolio of tools includes Simple Western systems that quantify protein expression and Biologics systems that probe the structure and purity of protein-based therapeutics.
Since 1988, PeproTech has grown into a global enterprise manufacturing an extensive line of Recombinant Human, Murine and Rat Cytokines, Animal-Free Recombinant Cytokines, Monoclonal Antibodies, Affinity Purified Polyclonal Antibodies, Affinity Purified Biotinylated Polyclonal Antibodies, ELISA Development Kits, Cell Culture Media Products and GMP Cytokines.
Euro Diagnostica offers versatile assay solutions and cutting-edge tools to pharma, biotech and CRO customers. Facilitating the development of safe and efficient drugs as well as an optimal treatment of patients, Euro Diagnostica is an optimal partner during the whole drug development continuum.
AllCells is a biotechnology company that provides hematological/immunological tissue products and expertise in bioservices worldwide. Our products include clinical grade tissue and primary cells, diseased cells, and whole blood for scientific research use. AllCells is fully certified in accordance with local, state and federal requirements and was established in 1998.
Myriad RBM, Inc. is the world’s leading multiplexed immunoassay testing laboratory, providing comprehensive protein biomarker services based on its Multi-Analyte Profiling (MAP) technology platform. This platform provides pre-clinical and clinical researchers with reproducible and quantitative data for a few or hundreds of proteins in a cost-effective manner.
Fidelta is a preclinical CRO offering services in ADME, Medicinal Chemistry, in vivo, in vitro and translational projects. We focus on the therapeutic areas involved in Respiratory, Inflammation, Fibrosis, Invectives and Oncology. Besides our standard models and assays, we also offer customized development and validation.
SomaLogic measure 1,310 proteins simultaneously from 65 µL of sample with high sensitivity, specificity and reproducibility. We enable biomarker discovery, better understanding of pathways, target identification, target validation and understanding of off-target effects. We can scale our technology from a large plex (1,310 proteins), to individual analytes, and to panels.
ABL, Inc. is a CMO/CRO with facilities in the US and Europe that provides diverse services for biologics development and manufacturing (protein and viral). ABL offers; PD, GMP manufacturing, preclinical and clinical development, comprehensive immunological services, clinical immunogenicity testing, GCLP trial sample processing and testing and many other services. www.ablinc.com
Using novel epigenetic technology, Epiontis provides precise and reproducible immunomonitoring services for clinical trials. The epigenetic PCR tests are based on in-house developed and IP protected markers specific for immune cell types (Treg, Th17, overall Tcells, etc.). Frozen whole blood or tissue can be used, permitting easy storage and logistics.